SCHEMBL24986047

SCHEMBL24986047

CCCC(C)Sc1ccc(N)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPK1 P28482 3/20 0.39
▸ TSHR P16473 3/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ TDP1 Q9NUW8 5/20 0.36
▸ ALDH1A1 P00352 4/20 0.36
▸ MAPT P10636 3/20 0.36
▸ HSP90AA1 P07900 1/20 0.36
▸ AGTR1 P30556 1/20 0.36
▸ ATM Q13315 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36
▸ SLC6A3 Q01959 1/20 0.34
▸ SERPINH1 P50454 2/20 0.34
▸ CYP19A1 P11511 1/20 0.34
▸ MAOA P21397 3/20 0.33
▸ MAOB P27338 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ PSMD14 O00487 1/20 0.33
▸ RECQL P46063 1/20 0.33
▸ GFER P55789 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11309197 0.83 MAPK1 (0.42) MAPK1TSHRCYP3A4TDP1ALDH1A1
SCHEMBL12112007 0.82 TSHR (0.41) MAPK1TSHRCYP3A4TDP1ALDH1A1
SCHEMBL10400659 0.80 MAOA (0.44) ALDH1A1SLC6A3MAOAMEN1KMT2A
SCHEMBL1454709 0.79 MAOA (0.41) MAPK1ALDH1A1MAPTMAOAMAOB
SCHEMBL12112005 0.74 TSHR (0.38) MAPK1TSHRCYP3A4TDP1ALDH1A1
SCHEMBL10474461 0.74 HTT (0.58) MAPK1TSHRALDH1A1MAPTKMT2A
SCHEMBL10474462 0.74 HTT (0.58) MAPK1TSHRALDH1A1MAPTKMT2A
SCHEMBL12112004 0.73 MAPK1 (0.50) MAPK1TSHRCYP3A4TDP1ALDH1A1
SCHEMBL2939873 0.73 MAPK1 (0.50) MAPK1TSHRCYP3A4TDP1ALDH1A1
SCHEMBL24398823 0.73 MAOA (0.42) MAPK1TSHRCYP3A4TDP1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) 2023-01-26 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230027295-A1 FXIA INHIBITORS AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF F11, TFPI, F7 MAPK1 2473/4885TSHR 2682/4885CYP3A4 232/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback